Table 2.
Comparison of characteristics for subtypes of AMD
| Classic CNV (n=13) | Occult CNV (n=18) | PCV (n=23) | P-value* | ||
|---|---|---|---|---|---|
| Age, years, mean ± SD (range) | 72.8±7.0 (59–84) | 76.7±5.5 (62–83) | 72.1±7.7 (52–86) | 0.073 | |
| Numbers of males/females | 9/4 | 15/3 | 11/12 | 0.060 | |
| Baseline logMAR visual acuity, mean ± SD | 0.59±0.29 | 0.40±0.30 | 0.36±0.35 | 0.048 | |
| Proportion of patients with changes in the BCVA of logMAR 0.3 or more (improvement/maintained/deterioration) | 3 months | 6/7/0 | 2/15/1 | 3/19/1 | 0.117 |
| 12 months | 7/3/1 | 1/14/0 | 2/19/2 | 0.001 | |
| Number of injections at 12 months, mean ± SD | 3.3±1.3 | 4.0±1.3 | 4.7±2.4 | 0.248 | |
| Change in NEI VFQ-25 composite scores at 3 months | 3.88±9.64 | −0.36±7.78 | 6.86±12.2 | 0.318 | |
| Change in NEI VFQ-25 composite scores at 12 months | 14.6±25.4 | 5.27±24.1 | 4.06±17.8 | 0.386 |
Notes:
*
Characteristics for each AMD types were compared using the Kruskal–Wallis test. A chi-square test was used to compare the proportion of improvement or deterioration in visual acuity.
Abbreviations: AMD, age-related macular degeneration; SD, standard deviation; CNV, choroidal neovascularization; PCV, polypoidal choroidal vasculopathy; NEI VFQ-25, 25-item National Eye Institute Visual Function Questionnaire; logMAR, logarithm of the minimum angle of resolution; BCVA, best-corrected visual acuity.